Farmington, Conn. – Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits of an investigational, once-a-day pill called brensocatib as a therapy for the chronic lung condition. The clinical trial findings are...
Latest News
Brentuximab vedotin produces durable responses and prolongs progression-free survival (PFS), when compared with physician’s choice of therapy, in previously treated patients with CD30-expressing cutaneous T-cell lymphoma (CTCL), according to final results from the ALCANZA study published in Blood Advances. The phase 3 ALCANZA trial (ClinicalTrials.gov Identifier: NCT01578499) enrolled 131 patients with mycosis...
Brentuximab vedotin produces durable responses and prolongs progression-free survival (PFS), when compared with physician’s choice of therapy, in previously treated patients with CD30-expressing cutaneous T-cell lymphoma (CTCL), according to final results from the ALCANZA study published in Blood Advances. The phase 3 ALCANZA trial (ClinicalTrials.gov Identifier: NCT01578499) enrolled 131 patients with mycosis...
(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patient Treatment well-tolerated and patient remains on study with stable disease elsewhere Sustained clinical response supports Bria-OTS personalized, off-the-shelf immunotherapy approach in Phase 1/2a metastatic breast cancer study PHILADELPHIA,...
SEONGNAM, South Korea and NEWTON, Mass — Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced that the company has initiated the Phase 1/2 clinical trial evaluating the safety, tolerability, and antitumor activity of BBT-207 in non-small cell lung cancer (NSCLC)...
PALO ALTO, Calif. — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for acoramidis, an investigational drug for the treatment of ATTR-CM. The...
PALO ALTO, Calif. and BERLIN, Germany — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and Bayer today announced a partnership wherein BridgeBio grants Bayer an exclusive license to commercialize acoramidis for ATTR-CM in Europe. In exchange, BridgeBio will receive up to $310 million USD comprising of upfront and near-term milestone payments,...
PALO ALTO, Calif. — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today reports positive topline results from FORTIFY, the Company’s Phase 3 pivotal study of BBP-418 in individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). BridgeBio will...
PALO ALTO, Calif. — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today shared positive results from the Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid with cardiomyopathy (ATTR-CM), conducted by Alexion, AstraZeneca Rare Disease. Results showed consistency to those...
PALO ALTO, Calif. — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced that updated data from CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment...